Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    KHK4083

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02647866
Recruitment Status : Completed
First Posted : January 6, 2016
Results First Posted : March 5, 2020
Last Update Posted : March 5, 2020
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin, Inc.

Brief Summary:
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC) followed by a Long-term Extension Therapy (LTE) phase for eligible subjects with a clinical response.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Digestive System Diseases Colitis, Ulcerative Colitis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases Colonic Diseases Autoimmune Disease Abdominal Pain Drug: KHK4083 Drug: Placebo Phase 2

Detailed Description:

A Phase 2, double-blind clinical study of multiple ascending doses of KHK4083 (or placebo) with an Long-term Extension Therapy (LTE) phase will be conducted in approximately 60 randomized adult subjects with moderately active UC who have a documented unsuccessful previous treatment.

The Treatment Period includes double-blind Induction Therapy (12 weeks) and Open-label Therapy (OLE) phase (40 weeks) for eligible subjects at Week 12. Subjects already enrolled in the double-blind, long-term extension (LTE) under preceding versions of the protocol who worsen may be eligible to transition to the OLE up to Week 28.

The Follow Up Period after the last administration will be for up to 16 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Double-blind Induction Therapy was separated into Part A for administration of multiple ascending IV doses of KHK4083 (or placebo) to subjects in Cohorts 1-3 and Part B for administration of the maximally tolerated dose (as determined in cohorts 1-3) in expansion cohort 4. Subjects in Part A were prohibited from participating in Part B.

Subjects in each cohort were randomly assigned in a 3:1 ratio to receive KHK4083 or placebo by IV infusion over 60 minutes (± 10 min.). Each subject received a total of 6 treatments (1 IV infusion per treatment) every 2 weeks from Week 0 (Day 1) to Week 10.

Subjects who completed double-blind Induction Therapy (i.e., at least 5 of 6 treatments) and had a clinical response or mucosal healing, as defined above, were eligible to continue in double-blind Long Term Extension Therapy (Weeks 12-52) & after protocol amendment all subjects who received at least 5 of 6 treatments were eligible for Open Label Extension Therapy (Weeks 12-52).

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Actual Study Start Date : June 2016
Actual Primary Completion Date : September 2018
Actual Study Completion Date : October 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: KHK4083 Cohort 1
Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
Drug: KHK4083
IV Infusion

Experimental: KHK4083 Cohort 2
Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
Drug: KHK4083
IV Infusion

Experimental: KHK4083 Cohort 3
Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
Drug: KHK4083
IV Infusion

Experimental: KHK4083 Cohort 4
Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
Drug: KHK4083
IV Infusion

Placebo Comparator: Placebo
Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
Drug: Placebo
IV Infusion




Primary Outcome Measures :
  1. Number of Subjects With Treatment-related Adverse Events [ Time Frame: Up to 52 weeks ]
    To determine the safety and tolerability of KHK4083

  2. Number of Subjects With Treatment-related Serious Adverse Events [ Time Frame: Up to 52 weeks ]
    To determine the safety and tolerability of KHK4083

  3. Number of Subjects Who Show Improvement in the Mucosa at Week 12 [ Time Frame: 12 weeks ]
    Measured by the modified Mayo endoscopy sub-score (mMES), which ranges from 0-3 with higher scores = more severe disease.

  4. Proportion of Subjects Who Show Improvement in the Mucosa at Week 52 [ Time Frame: 52 weeks ]
    Measured by the modified Mayo endoscopy sub-score (mMES), which ranges from 0-3 with higher scores = more severe disease.


Secondary Outcome Measures :
  1. Number of Subjects With Confirmed Anti-KHK4083 Antibodies (Immunogenicity) [ Time Frame: 52 weeks ]
    The immunogenicity was assessed by determination of the development of anti-drug antibodies (ADA) against KHK4083.

  2. Number of Subjects Who Achieve Mucosal Healing at Week 12 [ Time Frame: 12 weeks ]
    The endoscopic Mayo Score (Mayo endoscopic subscore) evaluates ulcerative colitis stage, based only on endoscopic exploration. The scale ranges from 0 to 3, with higher scores = more severe activity. Mucosal healing is defined as modified Mayo endoscopy sub-score (mMES) of 0 or 1 at Week 12.

  3. Number of Subjects Who Achieve Mucosal Healing at Week 52 [ Time Frame: 52 weeks ]
    The endoscopic Mayo Score (Mayo endoscopic subscore) evaluates ulcerative colitis stage, based only on endoscopic exploration. The scale ranges from 0 to 3, with higher scores = more severe activity. Mucosal healing is defined as modified Mayo endoscopy sub-score (mMES) of 0 or 1.

  4. Number of Subjects Who Achieve Clinical Improvement at Week 12 [ Time Frame: 12 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Improvement will be based on a reduction in the total Mayo Clinic score.

  5. Change From Baseline in Total Mayo Scale Score at Week 52 [ Time Frame: 52 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Improvement was based on a reduction (mean change from Baseline [Week 0] to Week 52) in the total Mayo Clinic score.

  6. Number of Subjects Who Achieve a Clinical Response at Week 12 [ Time Frame: 12 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical Response is a reduction in the total Mayo Clinic score of at least 3 points.

  7. Number of Subjects Who Achieve a Clinical Response at Week 52 [ Time Frame: 52 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical Response indicates the change from Baseline in the Total Mayo Clinic score <= -3 and the percentage change from Baseline in the Total Mayo Clinic score <= -30% to Week 12, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of <= 1.

  8. Number of Subjects Who Achieve Clinical Remission at Week 12 [ Time Frame: 12 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical remission is defined as a total Mayo Clinic score of ≤ 2 and no subscores > 1.

  9. Number of Subjects Who Achieve Clinical Remission at Week 52 [ Time Frame: 52 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical remission is defined as a total Mayo Clinic score of ≤ 2 and no subscores > 1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is able and willing to comply with study procedures, and to adhere to dosing, visit schedules and follow-up procedures as described in the protocol and ICF;
  2. Subject voluntarily signs/dates an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF in accordance with regulatory and Institutional Guidelines;
  3. Male and female subjects ≥ 18 years of age at the time of enrollment;
  4. Subject has UC that was diagnosed at least 6 months prior to the Screening visit;
  5. Subject has moderately active UC with a total Mayo score of 4-9 and an endoscopic sub-score of at least 2, with disease that extends at least 15 cm from the anal verge;
  6. Subject has had previous treatment (within 5 years prior to Screening) with one or more of the following: corticosteroids, immunosuppressive medications or TNF antagonist therapy that was unsuccessful because of a lack of efficacy response.
  7. Female subjects (WOCBP) must have a negative pregnancy test at Screening and Baseline. WOCBP must agree to use effective contraception;
  8. Male subjects (including those who have had a vasectomy) must use adequate contraception during the study and for at least 6 months after the last dose of investigational product.

Exclusion Criteria:

  1. Subject, who, for any reason, is judged by the Investigator to be inappropriate for this study;
  2. Subject has a medical history of other clinically significant diseases/disorders;
  3. Two or more biologic treatments with different mechanisms of action (e.g., infliximab, vedolizumab and golimumab) or Three or more anti-TNF biologics e.g. infliximab, adalimumab
  4. Subject requires prescription treatment for UC, except for the stable, oral treatment of UC for 4 weeks prior to screening.
  5. Subject has received any of the following prior treatments or treatments within the specified time prior to the Baseline visit:

    • Natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;
    • TNF antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);
    • Vedolizumab within 16 weeks;
    • Methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);
    • 5-ASA enema, steroid enema or suppository use within 2 weeks ; and/or Investigational agents within 8 weeks or 5 half-lives (whichever is longer).
  6. Subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for UC;
  7. Subject with known colonic dysplasia, adenomas or polyposis;
  8. Subject had major surgery within 4 weeks prior to Screening or an anticipated requirement for major surgery;
  9. Subject with enteric pathogens (including Clostridium difficile);
  10. Subject with any of the following hematological and chemistry laboratory values:

    • Platelet count < 100,000/mm3;
    • Neutrophils < 1500/mm3;
    • Serum creatinine ≥ 1.6 mg/dL (≥ 144.4 μmol/L);
    • Alkaline phosphatase > 3 times the upper limit of normal (ULN);
    • AST or ALT > 2 times ULN;
    • Total bilirubin > 2 mg/dL, unless due to Gilbert's Syndrome;
    • Serum albumin < 3 g/dL;
    • Hemoglobin < 9 g/dL;
    • Glycated serum hemoglobin A1c ≥ 9%.
  11. Subject has clinically significant cardiac disease;
  12. Subject is pregnant or breastfeeding;
  13. Subject has had major immunologic reaction;
  14. Subject is Hepatitis B core antibody or surface antigen positive and/or Hepatitis C antibody positive with detectable RNA;
  15. Subject has a history of human immunodeficiency virus (HIV) positivity, tests positive for HIV, or has congenital or acquired immunodeficiency;
  16. Subject has or has had active TB, suspected extra-pulmonary TB, a history of incompletely treated TB, or latent TB or other latent infection. Subjects with latent TB (clinical findings, purified protein derivative [PPD] or interferon gamma release assay [IGRA]) may be included in the study if prophylactic therapy for latent TB is started at least 4 weeks prior to Screening. Subjects with a potentially untreated other infection (clinical findings) are to be excluded.
  17. Subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.
  18. Subject has a history of systemic opportunistic infection or recurrent infections
  19. Subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.
  20. Subject who received a bacille Calmette-Guérin (BCG) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [MMR]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.
  21. Subject with a history of or active substance abuse.
  22. Subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02647866


Locations
Layout table for location information
United States, South Carolina
Greenville, South Carolina, United States, 29615
Czechia
Hradec Kralove, Czechia, 500 12
Znojmo, Czechia, 669 02
Hungary
Budapest, Hungary, 1125
Budapest, Hungary, H-1032
Budapest, Hungary, H-1083
Poland
Bydgoszcz, Poland, 85-168
Rzeszow, Poland, 35-302
Sopot, Poland, 81-756
Tychy, Poland, 43-100
Warsaw, Poland, 00-632
Warsaw, Poland, 03-580
Warsaw, Poland, 54-239
Romania
Bucharest, Sector 2, Romania, 020125
Russian Federation
Krasnoyarsk, Russian Federation, 660022
Moscow, Russian Federation, 129110
Novosibirsk, Russian Federation, 630091
Penza, Russian Federation, 440026
St. Petersburg, Russian Federation, 194354
St. Petersburg, Russian Federation, 196247
Serbia
Zemun, Belgrade, Serbia, 11080
Bežanija Kosa
Belgrade, Serbia, 11080
Kragujevac, Serbia, 34 000
Sponsors and Collaborators
Kyowa Kirin, Inc.
Investigators
Layout table for investigator information
Study Director: Vincent Strout, MBA Kyowa Kirin, Inc.
  Study Documents (Full-Text)

Documents provided by Kyowa Kirin, Inc.:
Study Protocol  [PDF] October 4, 2016
Statistical Analysis Plan  [PDF] October 6, 2017

Layout table for additonal information
Responsible Party: Kyowa Kirin, Inc.
ClinicalTrials.gov Identifier: NCT02647866    
Other Study ID Numbers: 4083-002
First Posted: January 6, 2016    Key Record Dates
Results First Posted: March 5, 2020
Last Update Posted: March 5, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Kyowa Kirin, Inc.:
4083-002
Intestinal Diseases
Ulcerative Colitis
UC
Mayo Clinic Scoring
Gastrointestinal Tract
Additional relevant MeSH terms:
Layout table for MeSH terms
KHK4083
Colitis
Colitis, Ulcerative
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Autoimmune Diseases
Ulcer
Abdominal Pain
Gastroenteritis
Pathologic Processes
Immune System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms, Digestive
Dermatologic Agents